ATryn from transgenic goats launched in the US
This article was originally published in Scrip
Lundbeck has launched the recombinant antithrombin product, ATryn, in the US, the first medicine to be manufactured in transgenic animals – goats. ATryn was approved in the US in February.
You may also be interested in...
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
European biotech Pharvaris has received series C funding to support its novel potential therapy for hereditary angioedema, in a competitive sector of drug development.